These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 27183521)

  • 1. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.
    Maurea N; Coppola C; Piscopo G; Galletta F; Riccio G; Esposito E; De Lorenzo C; De Laurentiis M; Spallarossa P; Mercuro G
    J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S19-26. PubMed ID: 27183521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.
    Maurea N; Coppola C; Piscopo G; Galletta F; Riccio G; Esposito E; De Lorenzo C; De Laurentiis M; Spallarossa P; Mercuro G
    J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e19-e26. PubMed ID: 27755239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.
    Maurea N; Spallarossa P; Cadeddu C; Madonna R; Mele D; Monte I; Novo G; Pagliaro P; Pepe A; Tocchetti CG; Zito C; Mercuro G
    J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1(Suppl 1):S93-S104. PubMed ID: 27183530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors.
    Tocchetti CG; Gallucci G; Coppola C; Piscopo G; Cipresso C; Maurea C; Giudice A; Iaffaioli RV; Arra C; Maurea N
    Eur J Heart Fail; 2013 May; 15(5):482-9. PubMed ID: 23325019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
    Zambelli A; Della Porta MG; Eleuteri E; De Giuli L; Catalano O; Tondini C; Riccardi A
    Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular adverse effects of targeted antiangiogenic drugs: mechanisms and management.
    Sundararajan S; Kumar A; Poongkunran M; Kannan A; Vogelzang NJ
    Future Oncol; 2016; 12(8):1067-80. PubMed ID: 26901457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.
    Maurea N; Spallarossa P; Cadeddu C; Madonna R; Mele D; Monte I; Novo G; Pagliaro P; Pepe A; Tocchetti CG; Zito C; Mercuro G
    J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e93-e104. PubMed ID: 27755247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer.
    Riondino S; Del Monte G; Fratangeli F; Guadagni F; Roselli M; Ferroni P
    Cardiovasc Hematol Agents Med Chem; 2017; 15(1):3-16. PubMed ID: 28137223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic and ethnic modulation of cardiovascular toxicity of vascular endothelial growth factor inhibitors.
    Chen YC; Chung CC; Lin YK; Chen YJ
    Ann Med; 2018 Feb; 50(1):46-56. PubMed ID: 28929822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy.
    De Keulenaer GW; Doggen K; Lemmens K
    Circ Res; 2010 Jan; 106(1):35-46. PubMed ID: 20056944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.
    Curigliano G; Cardinale D; Dent S; Criscitiello C; Aseyev O; Lenihan D; Cipolla CM
    CA Cancer J Clin; 2016 Jul; 66(4):309-25. PubMed ID: 26919165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis.
    Abdel-Qadir H; Ethier JL; Lee DS; Thavendiranathan P; Amir E
    Cancer Treat Rev; 2017 Feb; 53():120-127. PubMed ID: 28104567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention.
    Albini A; Pennesi G; Donatelli F; Cammarota R; De Flora S; Noonan DM
    J Natl Cancer Inst; 2010 Jan; 102(1):14-25. PubMed ID: 20007921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors.
    Kruzliak P; Novák J; Novák M
    Am J Hypertens; 2014 Jan; 27(1):3-13. PubMed ID: 24168915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiotoxic effects of angiogenesis inhibitors.
    Dobbin SJH; Petrie MC; Myles RC; Touyz RM; Lang NN
    Clin Sci (Lond); 2021 Jan; 135(1):71-100. PubMed ID: 33404052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Renal toxicity of anti-VEGF (corrected) targeted therapies].
    Vigneau C; Rioux-Leclercq N
    Nephrol Ther; 2013 Jun; 9(3):174-9. PubMed ID: 23410950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.
    Fedele C; Riccio G; Malara AE; D'Alessio G; De Lorenzo C
    Breast Cancer Res Treat; 2012 Jul; 134(2):595-602. PubMed ID: 22674190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients.
    Hall PS; Harshman LC; Srinivas S; Witteles RM
    JACC Heart Fail; 2013 Feb; 1(1):72-8. PubMed ID: 24621801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathophysiology of anthracycline cardiotoxicity.
    Mele D; Tocchetti CG; Pagliaro P; Madonna R; Novo G; Pepe A; Zito C; Maurea N; Spallarossa P
    J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S3-S11. PubMed ID: 27183523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors.
    Steingart RM; Bakris GL; Chen HX; Chen MH; Force T; Ivy SP; Leier CV; Liu G; Lenihan D; Lindenfeld J; Maitland ML; Remick SC; Tang WH
    Am Heart J; 2012 Feb; 163(2):156-63. PubMed ID: 22305831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.